Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD22-CAR m971-BBz lentiviral vector-transduced autologous T lymphocytes CRG-022

Autologous human T lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of an anti-CD22 single chain variable fragment (scFv) derived from the monoclonal antibody (moAb) 971 (m971), and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD22-CAR m971-BBz lentiviral vector-transduced autologous T lymphocytes CRG-022 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells. m971 binds to a membrane proximal epitope on CD22 and has a higher binding affinity compared to other anti-CD22 moAb.
Synonym:autologous anti-CD22-CAR m971-BBz T cells CRG-022
Code name:CRG 022
CRG-022
CRG022
Search NCI's Drug Dictionary